Southern Research Partners with Pathogenus to Expand Global Reach in Respiratory Disease and Cancer Research
核心洞察
Southern Research (搜索) and London-based Pathogenus Consulting (搜索) have signed a three-year renewable partnership to capitalize on growing global research opportunities in emerging and re-emerging diseases.
The collaboration will focus primarily on respiratory viruses including influenza (搜索), RSV (搜索), and COVID-19 (搜索), as well as viral diseases such as Dengue fever (搜索) and cancer (搜索) research.
Pathogenus will leverage its European network across the U.K., Ireland, Belgium, Switzerland, and the Netherlands to help Southern Research (搜索) expand its international client base and market share.
Birmingham-based Southern Research (搜索) has forged a strategic three-year partnership with London-based Pathogenus Consulting (搜索) to expand its global footprint in infectious disease and cancer (搜索) research, with particular emphasis on respiratory viruses and emerging pathogens.
The collaboration, which launched in January 2026, positions Southern Research (搜索) to capitalize on accelerating global investment in research while leveraging Pathogenus's established European network spanning the U.K., Ireland, Belgium, Switzerland, and the Netherlands.
Strategic Focus on Respiratory Diseases
Much of the partnership's emphasis will center on respiratory viruses including influenza (搜索), RSV (搜索), and COVID-19 (搜索), as well as viral diseases such as Dengue fever (搜索). The collaboration also extends to cancer (搜索) research, a longstanding focus area for Southern Research (搜索).
"We've seen clear momentum in our work with partners outside the United States, especially with Japan and European pharmaceutical companies, and the opportunity to broaden that footprint is both exciting and timely," said Fusataka Koide, senior director of global client engagement for Southern Research (搜索). "As global investment in research accelerates, this collaboration ensures we remain at the forefront of innovation that can improve health worldwide in the fight against emerging and re-emerging diseases."
Complementary Capabilities
The partnership combines Southern Research (搜索)'s scientific infrastructure, including its Biosafety Level 2 and 3 laboratories at its Birmingham headquarters, with Pathogenus's business development and marketing expertise. This combination aims to help international biotech companies developing treatments for emerging and re-emerging diseases access Southern Research's preclinical capabilities.
"Southern Research (搜索) has invested to excel in early-phase safety and efficacy testing with capabilities and capacity to match," said Adrian Wildfire, CEO of Pathogenus. "Pathogenus offers expert business development skills and marketing know-how to help Southern Research bring its models directly to clients and to grow its market-share. We look forward to a fruitful collaboration for both parties."
Organizational Background
Founded in Birmingham in 1941, Southern Research (搜索) operates as a nonprofit scientific research organization employing 200 scientists and professional staff. The organization has maintained an 80-year legacy of transformative research on cancer (搜索), infectious diseases, and other illnesses.
Pathogenus represents a consultancy formed by pharmaceutical industry and contract research organization experts, providing solutions across all phases of drug and vaccine development, including market penetration and sales strategies.
The initial three-year agreement includes provisions for renewal, potentially extending the collaboration beyond the initial term as both organizations seek to address the growing global demand for infectious disease research capabilities.